King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Naeem Chaudhri
Dr. Naeem Chaudhri is a Senior Consultant Hematologist and internationally recognised expert in chronic myeloid leukaemia (CML) and myeloproliferative neoplasms. He is a Hematologist (Chronic Leukemia & Myeloproliferative Neoplasms) with global experience in landmark CML clinical trials.
- 25+ years of experience treating CML, MPNs and performing allogeneic stem cell transplantation
- Global investigator for phase III clinical trials of next-generation CML therapies
- Expert in all lines of tyrosine kinase inhibitor therapy and TKI-resistance management
- Active contributor to international CML guideline and consensus groups
- Trusted worldwide for complex CML second opinions in Riyadh, Saudi Arabia
Qualifications & Credentials
Medical Degrees
- MD — Medical University
- Postgraduate specialisation in Internal Medicine and Hematology
Fellowships & Special Training
- Fellowship in Adult Hematology
- Fellowship in Hematopoietic Stem Cell Transplantation
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) Registration
- Member — American Society of Hematology (ASH)
- Member — European Hematology Association (EHA)
- Member — European LeukemiaNet CML Working Group
Areas of Expertise
Major Conditions Treated
- Chronic Myeloid Leukaemia (CML) — All Phases
- Essential Thrombocythaemia (ET)
- Polycythaemia Vera (PV)
- Primary Myelofibrosis
- Chronic Lymphocytic Leukaemia (CLL)
- Chronic Eosinophilic Leukaemia
- Systemic Mastocytosis
- Acute Leukaemia Requiring HSCT
Sub-specialties
- CML & Tyrosine Kinase Inhibitor Therapy: All lines of TKI therapy including asciminib — a leading Hematologist (Chronic Leukemia) specialist in Riyadh, Saudi Arabia.
- Myeloproliferative Neoplasms: JAK inhibitors, interferon and phlebotomy management for MPNs.
- Allogeneic HSCT for CML and MPNs: Transplantation for TKI-resistant or blast phase disease.
Advanced Procedures & Treatments
- First-Line TKI Therapy (Imatinib, Dasatinib, Nilotinib)
- Second- and Third-Line TKI Therapy (Bosutinib, Ponatinib)
- STAMP Inhibitor Therapy (Asciminib)
- BCR::ABL1 Mutation Testing & Management
- Allogeneic Stem Cell Transplantation for Leukaemia
- JAK Inhibitor Therapy (Ruxolitinib) for MPNs
- Treatment-Free Remission (TFR) Monitoring in CML
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh, Saudi Arabia — Consultant, Chronic Leukemia / Myeloproliferative Neoplasms Section, Department of Hematology, Stem Cell Transplantation and Cellular Therapy (Present)
Past Affiliations
- Information not publicly available.
Academic & Research Roles
- Global investigator — ASCEMBL Phase III trial (asciminib in CML)
- Contributor — European LeukemiaNet CML recommendations
- Reviewer for peer-reviewed haematology and leukaemia journals
Key Achievements
- Co-author on the landmark ASCEMBL longer-term follow-up paper in Nature Leukemia (2023)
- Senior author / co-author on multiple CML publications from KFSHRC's 172+ adult CML cohort
- International reputation as a CML and MPN expert across the Middle East and globally
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Hematology (ASH)
- European Hematology Association (EHA)
- European LeukemiaNet CML Working Group
- European Society for Blood and Marrow Transplantation (EBMT)
Research & Publications
Published Papers (Selected)
- Hochhaus A, Rea D, Boquimpani C, ... Chaudhri N, et al. "Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL." Leukemia. 2023;37:617-626. DOI:10.1038/s41375-023-01829-9
- El Fakih R, Chaudhri N, Alfraih F, Rausch CR, Naqvi K, Jabbour E. "Complexity of chronic-phase CML management after failing a second-generation TKI." (2019). PMID:31739705
- Banjar H, Adelson D, Brown F, Chaudhri N. "Intelligent Techniques Using Molecular Data Analysis in Leukaemia: An Opportunity for Personalized Medicine Support System." BioMed Research International. 2017;2017:3587309. DOI:10.1155/2017/3587309
- Khalil SH, Abu-Amero KK, Al Mohareb F, Chaudhri NA. "Molecular Monitoring of Response to Imatinib in Chronic Myeloid Leukemia Patients." Genetic Testing and Molecular Biomarkers. 2010;14(1):67-74. DOI:10.1089/gtmb.2009.0126
- Banjar H, Ranasinghe D, Brown F, ..., Chaudhri N. "Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia." PLOS ONE. 2017. DOI:10.1371/journal.pone.0168947
Ongoing Research & Clinical Interests
- CML treatment-free remission and deep molecular response
- STAMP inhibitor therapy (asciminib) in TKI-resistant CML
- Machine learning models for predicting CML response
- HSCT in advanced-phase CML and TKI-failure patients
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (SAR) | Estimated Cost (USD) |
|---|---|---|
| Haematology Consultation | SAR 500 – SAR 1,500 | $135 – $400 |
| BCR::ABL1 Molecular Monitoring | SAR 1,500 – SAR 4,000 | $400 – $1,065 |
| TKI Therapy (per month, drug-dependent) | SAR 8,000 – SAR 40,000 | $2,135 – $10,665 |
| Asciminib / Ponatinib Therapy (per month) | SAR 25,000 – SAR 60,000 | $6,660 – $16,000 |
| Allogeneic HSCT (package) | SAR 300,000 – SAR 600,000 | $80,000 – $160,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Naeem Chaudhri use in Hematologist (Chronic Leukemia & Myeloproliferative Neoplasms) treatment?
Dr. Naeem Chaudhri uses all generations of tyrosine kinase inhibitors, including STAMP inhibitors such as asciminib, alongside BCR::ABL1 mutation testing, deep molecular monitoring (digital PCR), JAK inhibitors for MPNs, and allogeneic stem cell transplantation. Remote second opinions on CML and MPN cases are available via Cancer Rounds.
2. What conditions does Dr. Naeem Chaudhri specialize in treating?
Dr. Naeem Chaudhri is a Hematologist (Chronic Leukemia & Myeloproliferative Neoplasms) specialist treating chronic myeloid leukaemia (CML), polycythaemia vera, essential thrombocythaemia, primary myelofibrosis, chronic lymphocytic leukaemia, and TKI-resistant leukaemias. International patients seeking the best CML doctor in Riyadh, Saudi Arabia are welcomed.
3. How do I book an appointment with Dr. Naeem Chaudhri?
Appointments with Dr. Naeem Chaudhri can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Naeem Chaudhri?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Naeem Chaudhri, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Naeem Chaudhri offer second opinions for Hematologist (Chronic Leukemia & Myeloproliferative Neoplasms) cases?
Yes. Second opinion consultations for complex CML, TKI-resistance and MPN cases can be arranged via Cancer Rounds with Dr. Naeem Chaudhri, an internationally recognised Hematologist (Chronic Leukemia & Myeloproliferative Neoplasms) specialist in Riyadh, Saudi Arabia.
